<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728558</url>
  </required_header>
  <id_info>
    <org_study_id>ANZIC-RC/YS003</org_study_id>
    <nct_id>NCT01728558</nct_id>
  </id_info>
  <brief_title>Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients</brief_title>
  <acronym>SPICE III RCT</acronym>
  <official_title>Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients: a Prospective Multicentre Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australian and New Zealand Intensive Care Research Centre</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Use of sedative drugs in intensive care is widespread. A cohort study conducted in
      Australia and New Zealand in 2010 revealed a high prevalence of deep sedation within the
      first 48 hours of mechanical ventilation which was independently linked to prolonged
      ventilation, hospital and 180 days mortality. Clinical practice is moving towards the use of
      lighter levels of sedation. Recent RCTs in Europe (JAMA 2012) and previous RCTs (JAMA 2009)
      supports growing evidence that dexmedetomidine facilitates rousable sedation, shortens
      ventilation time and attenuates delirium when compared to midazolam and propofol.

      The investigators confirmed in a pilot study the feasibility, efficacy and safety of a
      process of care known as Early Goal Directed Sedation (EGDS) that delivers:

        1. Early randomization after intubation or arrival in the ICU (intubated).

        2. Early Adequate analgesia after randomization.

        3. Goal directed sedation titrated to achieve light sedation.

        4. Dexmedetomidine based algorithm as the primary sedative agent with avoidance of
           benzodiazepines.

      The aim of this study is to assess the effectiveness of Early Goal Directed Sedation when
      compared to standard care sedation in critically ill patients.

      The study hypothesis is that Early Goal-Directed Sedation (EGDS), compared to standard care
      sedation, reduces 90-day all-cause mortality in critically ill patients who require
      mechanical ventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a large-scale study into the effectiveness of a novel approach for sedation in
      ventilated critically ill patients. The primary aim of this study is to determine whether
      Early Goal Directed Sedation therapy, compared to standard care sedation, reduces 90-day
      mortality in critically ill patients ventilated &gt; 24 hrs.

      The study will be a randomized, unblinded, controlled trial conducted in approximately 35-50
      intensive care units (ICUs) and will recruit 4000 mechanically ventilated patients (life
      support) who are expected to remain on the ventilator &gt; 24 hours AND require immediate
      ongoing sedative medication for comfort, safety, and to facilitate the delivery of life
      support measures, including mechanical ventilation.

      Patients with primary brain injury or prolonged weakness are excluded. Participants will be
      randomized into one of 2 study groups. All patients will receive adequate analgesia at
      randomization at the discretion of treating clinician. All randomized patients will have
      Light sedation as the default target unless otherwise clinically indicated. The intervention
      group will receive EGDS with dexmedetomidine as the primary sedative agent to achieve light
      sedation, with the addition of propofol as required. The use of benzodiazepines in the
      intervention group is not allowed, with the exception of specific, defined circumstances.

      The control group will have sedation according to usual practice as chosen by the treating
      clinician.  The use of dexmedetomidine is not allowed, with the exception of specific,
      defined circumstances.

      Deidentified data will be collected and will include; Baseline demographic information;
      Doses of all sedative, analgesic and other related medications; Pain, sedation and delirium
      scores and major treatments such as ventilation time, tracheostomy and dialysis. Patients
      surviving to hospital discharge will be contacted by phone to determine independent survival
      status at 90 days and again at 180 days plus Health Related Quality of Life and cognitive
      function assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90 post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilation free days</measure>
    <time_frame>at 28 days following randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of RASS measurements in target range</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of delirium measured by delirium free days</measure>
    <time_frame>up to  28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>up to 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who receive a tracheostomy Proportion of patients who require: re-intubation, physical restraints,or   unplanned extubation,</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of midazolam, propofol, dexmedetomidine, fentanyl, and morphine</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment with midazolam, propofol, dexmedetomidine, fentanyl, and morphine</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at hospital discharge</measure>
    <time_frame>at hospital discharge up to 180 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to ICU</measure>
    <time_frame>at 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D questionnaire</measure>
    <time_frame>at 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>at 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at ICU discharge</measure>
    <time_frame>up to 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full time institutional dependency at 180 days</measure>
    <time_frame>up to 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge destination</measure>
    <time_frame>up to 180 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Critical Illness and Mechanical Ventilation</condition>
  <arm_group>
    <arm_group_label>Early Goal Directed Sedation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Early Goal Directed Sedation process of care involves:
Early delivery of proposed intervention, shortly after initiating mechanical ventilation;
Effective analgesia provided simultaneously and early (analgesia first).
Regular and frequent assessment of patient wakefulness/sedative state;
Avoidance of benzodiazepines and minimisation of use of propofol;
Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.
Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care Sedation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early goal Directed Sedation</intervention_name>
    <arm_group_label>Early Goal Directed Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care sedation</intervention_name>
    <arm_group_label>Standard care Sedation Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been intubated and is receiving mechanical ventilation

          -  The treating clinician expects that the patient will remain intubated until the day
             after tomorrow (unlikely to be extubated the following day).

          -  The patient requires immediate ongoing sedative medication for comfort, safety, and
             to facilitate the delivery of life support measures.

        Exclusion Criteria:

          -  Age less than 18 years

          -  Patient is pregnant and/or lactating

          -  Has been intubated (excluding time spent intubated within an operating theatre or
             transport) for greater than 12 hours in an intensive care unit.

          -  Proven or suspected acute primary brain lesion such as traumatic brain injury,
             intracranial haemorrhage, stroke, or hypoxic brain injury.

          -  Proven or suspected spinal cord injury or other pathology that may result in
             permanent or prolonged weakness.

          -  Admission as a consequence of a suspected or proven drug overdose or burns.

          -  Administration of ongoing neuromuscular blockade.

          -  A mean arterial blood (MAP) pressure that is less than 50 mmHg despite adequate
             resuscitation and vasopressor therapy at time of randomisation

          -  Heart rate less than 55 beats per minute unless the patient is being treated with a
             beta-blocker or a high grade atrio-ventricular block in the absence of a functioning
             pacemaker.

          -  Known sensitivity to any of the study medications or the constituents of propofol
             (egg, soya or peanut protein)

          -  Acute fulminant hepatic failure

          -  Patient has been receiving full time residential nursing care.

          -  Death is deemed to be imminent or inevitable during this admission and either the
             attending physician, patient or substitute decision maker is not committed to active
             treatment.

          -  Patient has an underlying disease that makes survival to 90 days unlikely

          -  Patient has been previously enrolled in the SPICE study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahya Shehabi, MD, FCICM, FANZCA, EMBA</last_name>
    <role>Study Chair</role>
    <affiliation>University New South Wales, Prince of Wales Hospital, ANZIC-RC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinaldo Bellomo</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC &amp; Austin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve A. R Webb</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC &amp; Royal Perth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael C Reade</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC, Royal Brisbane &amp; Women's Hospital, Department of Military Medicine and Surgery,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belinda D Howe</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonie Weisbrodt</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC, Nepean Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian M Seppelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC, Nepean Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colin McArthur</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC, Auckland Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Erikson</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynne Murray</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANZIC-RC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Belinda D Howe, RN</last_name>
    <phone>+61 3 9903 0340</phone>
    <email>belinda.howe@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynne Murray</last_name>
    <phone>+61 3 99030343</phone>
    <email>lynne.murray@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2138</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Kol</last_name>
      <email>mark.kol@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Mark Kol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priya Nair</last_name>
      <email>pnair@stvincents.com.au</email>
    </contact>
    <investigator>
      <last_name>Priya Nair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hornsby Ku-ring-gai Hospital</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Fratzia</last_name>
      <phone>61412211913</phone>
      <email>jfratzia@nsccahs.health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>James Fratzia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lismore Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig McCalman</last_name>
      <email>craig.mccalman@ncahs.health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Craig McCalman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian M Seppelt</last_name>
      <email>seppelt@med.usyd.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Leonie Weisboldt</last_name>
      <email>leonie.weisbrodt@sydney.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Seppelt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yahya Shehabi</last_name>
      <phone>+61 2 9382 4721</phone>
      <email>y.shehabi@unsw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Yahya Shehabi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital</name>
      <address>
        <city>Tiwi</city>
        <state>Northern Territory</state>
        <zip>0811</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dianne Stephens</last_name>
      <email>dianne.stephens@nt.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dianne Stephens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast Hospital (Nambour Hospital)</name>
      <address>
        <city>Buderim</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Garrett</last_name>
      <email>peter_garrett@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Peter Garrett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Udy</last_name>
      <email>Andrew_Udy@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Andrew Udy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redcliffe Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Warhurst</last_name>
      <email>Tim_Warhurst@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Tim Warhurst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital &amp; Health Service</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Winearls</last_name>
      <email>JAMES_WINEARLS@HEALTH.QLD.GOV.AU</email>
    </contact>
    <investigator>
      <last_name>James Winearls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toowoomba Hospital</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Visser</last_name>
      <email>adam_visser@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Adam Visser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bala Venkatesh</last_name>
      <email>bmvenkat@bigpond.net.au</email>
    </contact>
    <investigator>
      <last_name>Bala Venkatesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Cooper</last_name>
      <email>david.cooper@dhhs.tas.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Brain</last_name>
      <email>matt.brain@dhhs.tas.gov.au</email>
    </contact>
    <investigator>
      <last_name>Matthew Brain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bendigo Hospital</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Edington</last_name>
      <email>JEdington@bendigohealth.org.au</email>
    </contact>
    <investigator>
      <last_name>John Edington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dandenong Hospital</name>
      <address>
        <city>Dandenong</city>
        <state>Victoria</state>
        <zip>3175</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjiv Vij</last_name>
      <email>vijsanjiv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Vij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angaj Ghosh</last_name>
      <email>angaj.gosh@nh.org.au</email>
    </contact>
    <investigator>
      <last_name>Angaj angaj.gosh@nh.org.au</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Botha</last_name>
      <email>JBotha@phcn.vic.gov.au</email>
    </contact>
    <investigator>
      <last_name>John Botha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Green</last_name>
      <email>DAVIDGR@barwonhealth.org.au</email>
    </contact>
    <investigator>
      <last_name>David Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinaldo Bellomo</last_name>
      <phone>+61 3 9496 5992</phone>
      <email>Rinaldo.bellomo@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Rinaldo Bellomo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Rechnitzer</last_name>
      <email>thomas.rechnitzer@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Tom Rechnitzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Santamaria</last_name>
      <email>john.santamaria@svhm.org.au</email>
    </contact>
    <investigator>
      <last_name>John Santamaria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Gippsland Health Service</name>
      <address>
        <city>Sale</city>
        <state>Victoria</state>
        <zip>3850</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Dennett</last_name>
      <email>jenny.dennett@cghs.com.au</email>
    </contact>
    <investigator>
      <last_name>Jennifer jenny.dennett@cghs.com.au</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steve Webb</last_name>
      <email>steve.webb@uwa.edu.au</email>
    </contact>
    <investigator>
      <last_name>Steve Webb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyell McEwan Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mrudula Kanhere</last_name>
      <email>mrudulaharsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mrudula Kanhere</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Clark</last_name>
      <email>peter_clark@wsahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Peter Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital CVICU</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shay McGuinness</last_name>
      <email>shaymc@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Shay McGuinness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony Williams</last_name>
      <email>tony.williams@cmdhb.org.nz</email>
    </contact>
    <investigator>
      <last_name>Tony Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Addington</city>
        <state>Christchurch</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seton Henderson</last_name>
      <email>Seton.Henderson@cdhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Seton Henderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>North Shore City</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Bevans</last_name>
      <email>Robert.Bevan@waitematadhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Robert Bevans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Dinsdale</last_name>
      <email>Dick.Dinsdale@ccdhb.org.nz</email>
    </contact>
    <investigator>
      <last_name>Richard Dinsdale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin McArthur</last_name>
      <email>ColinM@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Colin McArthur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawks Bay Hospital</name>
      <address>
        <city>Hastings</city>
        <zip>4156</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ross Freebairn</last_name>
      <email>ross.freebairn@xtra.co.nz</email>
    </contact>
    <investigator>
      <last_name>Ross Freebain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <reference>
    <citation>Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C, Seppelt IM, Webb S, Weisbrodt L; Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators and the ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012 Oct 15;186(8):724-31. doi: 10.1164/rccm.201203-0522OC. Epub 2012 Aug 2.</citation>
    <PMID>22859526</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Delirium</keyword>
  <keyword>Goal Directed</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Mortality</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Critically Ill</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
